Moderna Receives Health Canada Approval for RSV Vaccine for …
6 days ago · mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory ...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · CNN — The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under...
Moderna Receives European Commission Approval for RSV Vaccine …
Aug 23, 2024 · CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by …
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to ... - MedCity News
May 31, 2024 · Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their...
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, or RSV, infection.
Moderna Announces mRNA-1345, an Investigational ...
Jan 17, 2023 · mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults. mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB. Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval.
Moderna Receives Health Canada Approval for RSV Vaccine for …
6 days ago · mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...
mRNA vaccine effective against RSV respiratory disease - Nature
Feb 15, 2023 · Moderna has announced topline results for its mRNA-based vaccine against respiratory syncytial virus (RSV) infection in adults 60 years of age and older. mRNA-1345 targets the RSV fusion...
FDA approves mRNA-based RSV vaccine - Nature
Jun 7, 2024 · The FDA has approved Moderna’s mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) to protect adults aged 60 years and older from lower respiratory tract disease....